What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice […]

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year

Patients, caregivers and advocates across the US are calling for passage of the SOAR Act (Supplemental Oxygen Access Reform Act), a bipartisan bill aimed at improving access to supplemental oxygen for over 1.5 million Americans with serious lung and heart conditions — including portable, high-flow liquid oxygen, which is often unreliable, delayed, or simply unavailable under current

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year Read Post »

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has approved an update to the US label for WINREVAIR (sotatercept-csrk), Merck’s activin signaling inhibitor for pulmonary arterial hypertension, to include efficacy and safety data from the Phase 3 HYPERION trial. The trial specifically evaluated adults newly diagnosed with pulmonary arterial hypertension — within 12 months of screening,

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension Read Post »

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care!

The Alliance for Pulmonary Hypertension (AfPH) is back with the third instalment of their 2026 webinar series exploring how new science and AI are transforming pulmonary arterial hypertension care. This session taking place on September 28 at 6 pm CEST brings together leading experts from the US, UK, and Netherlands to explore where the field

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care! Read Post »

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026

The French Pulmonary Hypertension Association HTaPFrance is holding its 6th Patient Congress, 13–15 November 2026 at Centre Valpré in Écully, France — coinciding with the association’s 30th anniversary. The congress is open to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH patients, those awaiting or having received a transplant, along with their families,

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026 Read Post »

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

The findings of the Pulmovant Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD, Group 3 of the World Health Organisation, WHO, pulmonary hypertension classification) were presented on September 8, 2026, at the European Respiratory Society (ERS) International Congress 2026 by Marc Humbert, MD, PhD, Professor of Respiratory Medicine

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026

The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress! The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session. Here is the link to the article: https://lnkd.in/evX7wHhe Pisana Ferrari, President of

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026 Read Post »

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026

The September issue of Journal of Heart and Lung Transplant presents new data pointing to sodium-glucose cotransporter 2 (SGLT2) inhibitors — drugs like dapagliflozin and empagliflozin, originally developed for diabetes — as a potential novel avenue for treating pulmonary arterial hypertension. Initially valued for their effect on kidney glucose reabsorption, sodium-glucose cotransporter 2 (SGLT2) inhibitors

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1

Following the 7th World Symposium on Pulmonary Hypertension, a review published in the European Respiratory Journal summarises the current understanding of Pulmonary hypertension associated with interstitial lung disease (PH-ILD). It covers the condition’s clinical features, underlying biology, diagnosis, prognosis and treatment, while flagging diagnostic challenges — from overlapping symptoms to the lack of specific biomarkers

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1 Read Post »

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026

The US Food and Drug Administration (FDA) has accepted for review a New Drug Application from United Therapeutics Corporation for ralinepag, an investigational prostacyclin IP receptor agonist intended to treat pulmonary arterial hypertension (PAH). The filing rests on results from the Phase III ADVANCE OUTCOMES study See our previous article on this topic here. Read more at

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026 Read Post »

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition

A narrative review on inhaled pulmonary vasodilators (iPVs) in perioperative pulmonary hypertension (PH) management was published recently in Key points: Background: Pulmonary hypertension significantly raises perioperative morbidity/mortality risk, especially in cardiac and high-risk non-cardiac surgery. Traditional IV vasodilators (nitroglycerin, sodium nitroprusside) lack pulmonary selectivity and cause systemic hypotension. Established agents: The review compares five main

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition Read Post »

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026

For 30 years, pulmonary arterial hypertension (World Health Organisation, WHO, Group 1 pulmonary hypertension) treatment relied on three vasodilator-based pathways: endothelin receptor antagonists (bosentan, ambrisentan, macitentan), the nitric oxide/cGMP pathway (sildenafil, tadalafil, riociguat), and prostacyclin pathway agents (treprostinil, epoprostenol, selexipag, etc.). These improve symptoms and slow progression but don’t modify the underlying vascular disease, and

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026 Read Post »

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide

he pathway to medical breakthroughs is often laden with surprises, errors, and serendipity, reads and article in a magazine called Mirage. The article dates back to 2023 but we found it still relevant and interesting as it mentions two iaccidental discoveries, warfaring and sildenail citrate that are have transformed the care of pulmonary arterial hypertension

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide Read Post »

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026

Insmed announced on July 16 positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term safety, tolerability, and effectiveness of

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026 Read Post »

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning

The Pulmonary Vascular Research Iinstitute (PVRI’s) Access to Care Workstream has launched a new, free online service from clinicians around the world to bring anonymised complex pulmonary hypertension cases for discussion with a tailored panel of specialists. Global PH Consult is open to clinicians everywhere, with a primary focus on supporting those in low and

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning Read Post »

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor

Beyond hemodynamics and treatment targets, there are conversations with patients that rarely make it into clinical guidelines — yet they’re often the ones that matter most. That’s the message from Susanne McDevitt, DNP, a critical care nurse practitioner with the Pulmonary Hypertension (PH) Program at Michigan Medicine, University of Michigan, Ann Arbor. In a conversation

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor Read Post »

TRANSLATE »
Scroll to Top